Lenalidomide revenue dependency
Significant portion of U.S. growth attributed to lenalidomide; agreement ends January 2026, creating uncertainty beyond.
DRREDDY / bear-case history
Track the concerns that keep returning.
Dr. Reddy's Laboratories · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
high
Russia market volatility
Russia business grew 77% but on a low base; currency and geopolitical risks remain high.
India innovation execution risk
Top-5 aspiration relies on signing and commercializing multiple innovative products; timeline and uptake uncertain.
Price erosion normalization in U.S.
Current lower price erosion may be temporary; management noted model hasn't changed, implying potential reversion.
US price erosion in generics
Pricing pressure in some key products partially offset volume gains in North America.
Freight cost impact from Middle East conflict
Increased freight rates due to Red Sea route issues and air shipments added tens of crores to costs.
SG&A step-up sustainability
SG&A jumped 28% YoY; analyst questioned if one-offs were included. Management attributed to investments and freight, but full-year guidance implies normalization.
Cash flow moderation from factoring changes
Free cash flow was lower due to reduced factoring in the US; management expects normalization but it introduces volatility.
Lenalidomide revenue decline sharper than expected
Lenalidomide sales expected to drop significantly after Q2 FY26; magnitude depends on pricing and competitor behavior.
Semaglutide launch delays due to IP or regulatory hurdles
Canadian launch contingent on patent litigation outcome in India and FDA approval; any delay could push revenue to later quarters.
US generic price erosion persists
Base US business faces ongoing price erosion; management expects flat to single-digit growth but uncertainty remains.
SG&A costs may remain elevated
SG&A at 30% of sales in Q1; management targets 28-29% for full year, but NRT and nutraceutical investments could keep it higher.
FDA observations at Bachupally biologics facility
US FDA pre-approval inspection resulted in 9 observations. Management believes they are addressable but could delay biosimilar approvals if not resolved timely.
India business growth trajectory uncertainty
Despite guidance for double-digit growth by year-end, India business has been range-bound for several quarters. Analyst questioned the timeline for material step-up.
Price erosion in US generics
Price erosion remains a headwind, though moderating. Management noted it fluctuates between high single-digit to low double-digit, impacting revenue growth.
Dependence on US FDA approvals for complex launches
Launch of high-value products like Rituximab biosimilar in the US depends on FDA approval, which is uncertain and could be delayed.
Revlimid revenue sustainability
Revenue from lenalidomide (Revlimid) is subject to confidential agreements and competitive pressures; management declined to provide specific guidance on future sales.
Currency risk in Russia
Russia business faces unfavorable forex movements; despite hedging, devaluation could impact reported revenues.
Impairment risk from supply chain issues
A product faced procurement constraints from contract manufacturers, leading to a ₹92 crore impairment; similar issues could affect other products.
US FDA delays on biosimilar approvals
Rituximab BLA received a CRL; abatacept and semaglutide approvals face regulatory uncertainty.
Revlimid revenue decline
Revlimid sales are declining faster than expected, with Q3 likely the last quarter of meaningful contribution.
Semaglutide Canada pricing and competition
Multiple filers and potential compounding pharmacy entry could lead to aggressive pricing and lower margins.
Patent litigation outcome in India for semaglutide
Awaiting Delhi High Court decision; adverse ruling could delay India launch and impact export plans.
Potential OAI outcome at FTO-3 facility
FDA issued Form 483 with 10 observations at FTO-3; management has responded but risk of OAI classification could impact approvals and reputation.
US generic price erosion
Price erosion in US generics continues, though management describes it as stable. Any acceleration could pressure margins.
Dependence on Revlimid for cash flows
Revlimid contribution remains meaningful; any unexpected decline could impact cash generation and ability to invest in pipeline.
Supply chain disruptions from Red Sea crisis
Geopolitical tensions are causing sea route disruptions; management is building inventory but costs could rise if situation persists.
US FDA Form 483 at CTO2 facility
The US FDA issued a Form 483 with seven observations at the CTO2 facility in Bollaram, Hyderabad. Management has responded but resolution timeline is uncertain.
Lenalidomide revenue decline post-2025
Lenalidomide revenue is expected to decline significantly after September-October 2025 as volume restrictions end and competition intensifies.
Iron sucrose approval delay due to CRL
The company received a complete response letter (CRL) on the API side for iron sucrose, delaying the expected launch.
India business underperformance in cardiac and GI segments
Cardiac and gastrointestinal therapy areas are growing slower than the market; management expects recovery but timeline is uncertain.
Regulatory delays for biosimilars in U.S.
Denosumab received CRL from FDA due to partner Alvotech's facility issues; Rituximab requires re-inspection. Both face delays of at least 6-12 months.
Lenalidomide revenue cliff from Q4
CEO advised to assume zero lenalidomide revenue from Q4 FY26, which will impact overall revenue and margins.
Semaglutide pricing pressure and competition
Management expects eventual competition in Canada and other markets, with pricing likely settling at lower end of $20-$70 range.
SG&A cost growth moderation uncertain
SG&A as % of revenue remains elevated at 30% (ex-one-off); management expects growth to moderate but absolute level may not decline.
Price erosion in US generics
Management acknowledged price erosion on select large products, partially offset by other products. Continued erosion could pressure US margins.
Forex volatility in emerging markets
Emerging market growth in constant currency may be offset by unfavorable forex movements, particularly in Russia and other markets.
Biosimilar Rituximab CRL delays
US FDA issued a complete response letter for biosimilar Rituximab due to CMC questions; resolution expected around September, but timeline for approval remains uncertain.
Competition in Revlimid generic
Multiple new entrants in the generic Revlimid market could impact pricing and volume, though management declined to discuss specifics.
U.S. tariffs on generics
Potential tariffs on pharmaceutical imports could impact margins; management is working with customers to ensure supply continuity but uncertainty remains.
REVLIMID revenue cliff in January 2026
Exclusivity ends in January 2026, leading to significant revenue decline; management expects to offset through growth in other segments but risk remains.
Gross margin volatility from one-off costs
Q4 gross margin fell 300 bps due to manufacturing overhead and lower milestone income; while management considers it one-off, recurrence could pressure margins.
Semaglutide competition in Canada
Multiple players may launch generic semaglutide in Canada, leading to price erosion and lower-than-expected market share for Dr. Reddy's.
Semaglutide approval delays in Brazil
Brazil approval for semaglutide is delayed by 3-4 months, which could impact FY27 unit sales guidance of 12 million units.
Lenalidomide shelf-stock adjustment recurrence
A surprise INR 453 crore shelf-stock adjustment hit Q4 revenue; similar customer-driven adjustments could recur.
U.S. generics price erosion
U.S. generics revenue has been flat despite new launches, indicating significant price erosion that may continue.
CAR T and partnered asset discontinuation
Impairment of INR 135 crore on CAR T and INR 93 crore on partnered asset (Immutep) highlights R&D pipeline risk.